Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

484
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
484
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.8K
Drugs Acting on Autonomic Ganglia: Stimulants01:23

Drugs Acting on Autonomic Ganglia: Stimulants

2.0K

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.0K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.6K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Evaluation of a Limited Number of Histologic Levels in Prostate Needle Core Biopsies: Do Clinically Significant Cancer Parameters Go Undetected?

International journal of surgical pathology·2025
Same author

Primary Well-Differentiated Neuroendocrine Tumor of the Common Hepatic Duct.

International journal of surgical pathology·2025
Same author

Serous Carcinomas Initially Diagnosed on Colon Biopsies: A Case Series Highlighting the Role of p53 to Guide Management.

International journal of surgical pathology·2025
Same author

GATA3 positive spindle cell neoplasm involving the liver diagnosed as metastatic sarcomatoid chromophobe renal cell carcinoma at autopsy.

Histopathology·2025
Same author

Report of Active Surveillance for a Masson Tumor of Chest Wall With Spontaneous Resolution.

Thoracic cancer·2025
Same author

Piaget's 3-mountains task with impossible options: Sighted, blindfolded, early and late blind participants.

Perception·2023

相关实验视频

Updated: Jan 11, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.4K

与甲基胺使用相关的心房节点阻塞

Nicholas L Vitagliano1, Tyler Ky1, John M Kennedy2

  • 1Department of Internal Medicine, College Medical Center, Long Beach, CA, USA.

The American journal of case reports
|November 10, 2025
PubMed
概括

甲基胺的使用很少会导致严重的心律问题,如高度心房 (AV) 阻塞,导致心力衰竭. 早期识别这些心脏并发症对于及时干预和管理至关重要.

科学领域:

  • 心脏病学 心脏病学
  • 毒理学 毒理学 毒理学
  • 电力生理学 电力生理学

背景情况:

  • 甲基胺的使用量在全球范围内不断增加,特别是在年轻人中.
  • 心血管并发症是已知的风险,通常涉及QT延长和心律失常.
  • 高度的心房 (AV) 阻塞和肌节律失常是甲基胺毒性的罕见表现.

研究的目的:

  • 报告一种罕见的高度AV阻塞病例,这是由于甲基胺毒性的次要原因.
  • 为了突出在甲基胺使用者中不寻常的布拉迪亚心律失常的表现.
  • 强调识别和管理与甲基胺使用相关的心脏并发症的重要性.

主要方法:

  • 一个40岁男性的病例报告,他患有甲基胺依赖症.
  • 持续的遥测监测显示了2:1和3:1的AV封锁.
  • 电心电图 (ECG) 显示PR延长和暂时的心脏阻塞.
  • 心声学评估左心室喷射分数 (LVEF).
  • 心脏磁共振成像 (MRI) 用于双心脏功能和血栓检测.
  • 核成像用于排除粉样化症.

主要成果:

  • 患者出现心力衰竭 (呼吸不全,) 和胸痛的症状.

更多相关视频

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.7K
Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
09:20

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

Published on: July 5, 2021

3.5K

相关实验视频

Last Updated: Jan 11, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

3.4K
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.7K
Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice
09:20

Microelectrode Array Recording of Sinoatrial Node Firing Rate to Identify Intrinsic Cardiac Pacemaking Defects in Mice

Published on: July 5, 2021

3.5K
  • 远程测量和心电图证实过渡性高度AV阻塞 (2:1和 3:1) 与鼻高心率和脱有关.
  • 心声扫描显示严重的全球低运动和20%的LVEF.
  • 心脏MRI显示了严重的双心膜扩张和功能障碍.
  • 患者接受了可植入式心脏转换器-除器 (ICD) 进行初级预防.
  • 结论:

    • 甲基胺毒性可以揭露或引起远导系统疾病,导致严重的节律失常.
    • 这一案例强调了甲基胺可能诱导显著的心脏功能障碍和导电异常的潜力.
    • 对于患有这些并发症的患者来说,及时识别和管理,包括必要时永久节奏,至关重要.